Clinicians' perspectives on the use of fixed-dose combination of voglibose, glimepiride and metformin in managing type 2 diabetes mellitus in Indian settings

Manjula S.; Krishna Kumar M.

doi:10.18203/issn.2454-2156.IntJSciRep20252189

Authors

Manjula S. Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India
Krishna Kumar M. Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India

DOI:

https://doi.org/10.18203/issn.2454-2156.IntJSciRep20252189

Keywords:

Glimepiride, Glycemic control, Metformin, Postprandial glucose, Type 2 diabetes mellitus, Voglibose

Abstract

Background: To gather expert opinion on the use of fixed dose combination (FDC) of voglibose, glimepiride and metformin in managing type 2 diabetes mellitus (T2DM) in Indian settings.

Methods: This cross-sectional study was conducted among clinicians using a structured questionnaire on current feedback, clinical observations and specialists' experiences in managing T2DM, with a special emphasis on the use of FDC voglibose, glimepiride and metformin in routine practice. Descriptive statistics were used for data analysis, with graphs and pie charts for visualization.

Results: The study included 472 clinicians, with 64% preferring to manage elevated postprandial glycemic average hemoglobin A1c (PGA1c) levels using an FDC of alpha-glucosidase inhibitors (AGIs), sulfonylureas (SUs) and metformin. Voglibose therapy was reported by 73% of respondents as effective for PGA1c control, reducing glycemic variability, lowering hypoglycemic risk and being compatible with other oral antidiabetic drugs (OADs). Approximately 66% of experts preferred voglibose + SU + metformin FDC for elderly patients with elevated PGA1c levels. Around 80% found the combination of voglibose, glimepiride and metformin effective in managing all aspects of the glycemic hexad, including fasting and postprandial glucose, HbA1c, nocturnal hypoglycemia, glycemic variability and overall hypoglycemia. Additionally, 66% highlighted its role in reducing visceral and subcutaneous adipose tissue.

Conclusions: This study highlighted a strong clinician preference for voglibose, glimepiride and metformin FDC in T2DM management due to its effectiveness in controlling post-prandial blood glucose, reducing glycemic variability, minimizing hypoglycemia and improving the glycemic hexad, especially in elderly and high-risk patients.

Metrics

Metrics Loading ...

References

Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. DOI: https://doi.org/10.1016/j.diabres.2021.109119

International Diabetes Federation. Facts & figures. Available at: https://idf.org/about-diabetes/diabetes-facts-figures/. Accessed on 6 February 2025.

Kusunoki Y, Konishi K, Tsunoda T, Koyama H. Significance of Glycemic Variability in Diabetes Mellitus. Intern Med. 2022;1;61(3):281–90. DOI: https://doi.org/10.2169/internalmedicine.8424-21

U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995;44(11):1249–58. DOI: https://doi.org/10.2337/diabetes.44.11.1249

Kalra S, Das AK, Priya G, Ghosh S, Mehrotra RN, Das S, et al. Fixed-dose combination in management of type 2 diabetes mellitus: Expert opinion from an international panel. J Family Med Prim Care. 2020;9(11):5450–7. DOI: https://doi.org/10.4103/jfmpc.jfmpc_843_20

Chawla R, Madhu SV, Makkar BM, Ghosh S, Saboo B, Kalra S, et al. RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. Indian J Endocrinol Metab. 2020;24(1):1–122. DOI: https://doi.org/10.4103/ijem.IJEM_225_20

Joshi SR, Standl E, Tong N, Shah P, Kalra S, Rathod R. Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review. Expert Opin Pharmacother. 2015;16(13):1959–81. DOI: https://doi.org/10.1517/14656566.2015.1070827

Voglibose - an overview. ScienceDirect Topics. Available at: https://www.sciencedirect.com. Accessed on 21 January 2025.

Kaku K. Efficacy of voglibose in type 2 diabetes. Expert Opinion on Pharmacotherapy. 2014;15(8):1181–90. DOI: https://doi.org/10.1517/14656566.2014.918956

Dabhi AS, Bhatt NR, Shah MJ. Voglibose: An Alpha Glucosidase Inhibitor. J Clin Diagn Res. 2013;7(12):3023–7.

Göke B, Fuder H, Wieckhorst G, Theiss U, Stridde E, Littke T, et al. Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion. 1995;56(6):493–501.

Göke B, Fuder H, Wieckhorst G, Theiss U, Stridde E, Littke T, et al. Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion. 1995;56(6):493-501. DOI: https://doi.org/10.1159/000201282

Trerattanavong K, Tadi P. Glimepiride. In: StatPearls. Treasure Island (FL): StatPearls. Available at: http://www.ncbi.nlm.nih.gov/books. Accessed on 21 February 2025.

Pernicova I, Korbonits M. Metformin--mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10(3):143–56. DOI: https://doi.org/10.1038/nrendo.2013.256

Das AK, Wangnoo SK, Chawla R, Shaikh A, Bantwal G, Kalra P, et al. Expert Consensus on Triple Combination of Glimepiride, Metformin and Voglibose Usage in Patients with Type 2 Diabetes Mellitus in Indian Settings. J Diabetol. 2022;13(2):145. DOI: https://doi.org/10.4103/jod.jod_118_21

Parmar N, Gupta AK, Jhaveri K, A B, Chhaya G, Kansara S, et al. Real-World Assessment of Personalized Approach With Voglibose Fixed-Dose Combination in Type 2 Diabetes Mellitus. Cureus. 2023;16(4):57494. DOI: https://doi.org/10.7759/cureus.57494

Derosa G, Salvadeo SAT, D’Angelo A, Ferrari I, Mereu R, Palumbo I, et al. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. Curr Med Res Opin. 2009;25(3):607–15. DOI: https://doi.org/10.1185/03007990802711024

Kalra S, Selvam AP, Shah AV, Neelaveni K, Agrawal N, Das S, et al. Prospective Multicenter Observational Study of Voglibose in Type 2 Diabetes—VICTORY. US Endocrinol. 2020;16(1):31. DOI: https://doi.org/10.17925/USE.2020.16.1.31

Kumar L, Gupta SK, Prakash A. Assessment of the prescription pattern of anti-diabetic drugs in type-2 diabetes mellitus patients. Pharma Innovation J. 2018;7(5):392-4.

Santra D, Totade S. Prescribing Trends of Antidiabetic Fixed dose combinations in a rural tertiary care teaching hospital in Central India: An Observational, cross-sectional study. Res J Pharmacol Pharmacodynamics. 2015;29;7(1):19–22. DOI: https://doi.org/10.5958/2321-5836.2015.00004.X

Jindal A, Jindal M, Kaur M, Kumar R. Efficacy and safety of voglibose as an add-on triple drug in patients of type two diabetes mellitus uncontrolled with glimepiride and metformin in punjabi population. Ind J Basic Appl Med Res. 2014;3(3):111-6.

Saito N, Sakai H, Suzuki S, Sekihara H, Yajima Y. Effect of an α-Glucosidase Inhibitor (Voglibose), in Combination with Sulphonylureas, on Glycaemic Control in Type 2 Diabetes Patients. J Int Med Res. 1998;26(5):219–32. DOI: https://doi.org/10.1177/030006059802600501

Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106(4):453–8. DOI: https://doi.org/10.1172/JCI10762

Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):122. DOI: https://doi.org/10.1186/s12933-018-0762-4

Rao C, Faruqui A. Efficacy and safety of oral triple drug combination (voglibose, glimepiride and metformin) in the management of type 2 diabetes mellitus. Int J Curr Res Rev. 2013;5(16):20-26.

Murti K, Sethi MK, Dey A, Lal CS, Pandey K, Das P. Addition of Voglibose to Glimepiride and Metformin have Better Glucose Control in Diabetics: A Prospective, Parallel-groupand Open-label Comparative Study. Int J Pharmacol. 2016;12(4):422–8. DOI: https://doi.org/10.3923/ijp.2016.422.428

Takami K, Takeda N, Nakashima K, Takami R, Hayashi M, Ozeki S, et al. Effects of dietary treatment alone or diet with voglibose or glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2002;25(4):658–62. DOI: https://doi.org/10.2337/diacare.25.4.658

Fujitaka K, Otani H, Jo F, Jo H, Nomura E, Iwasaki M, et al. Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome. Endocrin J. 2011;58(6):425–32. DOI: https://doi.org/10.1507/endocrj.K10E-327

Faruqui AA. Safety and Efficacy of Fixed Dose Combination of Voglibose, Glimepiride and Metformin in Indian Type 2 Diabetes Mellitus Patients. Adv Diab Metab. 2016;4(3):49–54. DOI: https://doi.org/10.13189/adm.2016.040302

Shamanna P, Jha PK, Makwana A, Shukla H, Bavishi C. Observational, Multicenter, Retrospective, Study on the Usage Patterns of the Fixed Dose Combination of Glimepiride, Metformin and Voglibose in Type 2 Diabetes Management. Cureus. 2024;16(1):52064. DOI: https://doi.org/10.7759/cureus.52064

Nigam N, Anand P, Kumar S, Manchi RK. Comparative study of efficacy and safety of metformin+glimepiride vs metformin+glimepiride + voglibose in type 2 diabetes mellitus patients at tertiary care centre, Kanpur. J Advan Scient Res. 2021;12(2):204–7.